• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oruka Therapeutics, Inc. - Common Stock (NQ:ORKA)

71.93 -1.94 (-2.63%)
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,388,191
Open 73.75
Bid (Size) 71.93 (4,700)
Ask (Size) 72.01 (1,100)
Prev. Close 73.87
Today's Range 70.50 - 74.26
52wk Range 25.11 - 115.52
Shares Outstanding 14,410,143
Dividend Yield 26.91%
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
These 2 Stocks Have Run Circles Around the Magnificent Seven This Year, and Wall Street Says There Is More Upside Ahead ↗
October 15, 2026
Innovation pays off. 
Via The Motley Fool
News headline image
Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
September 23, 2026
From Oruka Therapeutics, Inc.
Via GlobeNewswire

Performance

52-Week Range 37.7% below 52-week high
71.93
25.1152W Low 115.5252W High
1 Week 13.3% below 1-week high
73.151W Low 82.951W High

Oruka Therapeutics, Inc. - Common Stock (ORKA) traded between $25.11 and $115.52 over the past 52 weeks and last traded at $71.93, 37.7% below its 52-week high. Over the past week it ranged between $73.15 and $82.95.

Past 12 Months
-12.4%
-22.0%
-13.4%
+7.2%
+154.4%
+157.7%
1W -$10.18
1M -$20.27
3M -$11.11
6M +$4.86
YTD +$43.66
1Y +$44.02

ORKA was +157.7% over the past year, +7.2% over six months, +154.4% year to date, -12.4% in the last week.

12 Months vs Market
ORKA
+157.7%
DIA
+12.2%
SPY
+14.7%
QQQ
+17.9%
IWM
+8.0%

Over the past 12 months ORKA returned +157.7% versus DIA (Dow) +12.2%, SPY (S&P 500) +14.7%, QQQ (Nasdaq 100) +17.9% and IWM (Russell 2000) +8.0%.

Volume & Liquidity 1.54× 3-mo avg
Today 1,388,191 3-mo avg 900.8K
1W
832.0K
1M
1.0M
3M
900.8K
6M
1.3M
YTD
1.1M
1Y
965.9K

ORKA most recently traded 1,388,191 shares against a 3-month average daily volume of 900.8K.

More News

Read More
News headline image
Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference
September 09, 2026
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
August 24, 2026
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 10, 2026
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean ↗
June 27, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors? ↗
June 24, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
An Oruka Therapeutics (ORKA) Insider Sold 105,000 Shares Worth $6.2 Million ↗
May 31, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
May 28, 2026
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120% ↗
May 13, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company ↗
May 13, 2026
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally ↗
May 13, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 13, 2026
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried? ↗
May 11, 2026
Via The Motley Fool
News headline image
Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering
April 28, 2026
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering
April 27, 2026
From Oruka Therapeutics, Inc.
Via GlobeNewswire
These stocks are gapping in today's session ↗
April 27, 2026
Via Chartmill
Top movers in Monday's pre-market session ↗
April 27, 2026
Via Chartmill
News headline image
Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis
April 27, 2026
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026
April 26, 2026
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Insider Sells $463K in Stock as Shares Skyrocket 650%, but Here's What Matters for Investors ↗
April 21, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗
March 18, 2026
Via The Motley Fool
News headline image
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗
March 18, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
VR Adviser Adds Over 1 Million Savara Shares ↗
March 15, 2026
Via The Motley Fool
Topics Regulatory Compliance
Let's take a look at the stocks that are in motion in today's session. ↗
March 13, 2026
Via Chartmill

Frequently Asked Questions

Is Oruka Therapeutics, Inc. - Common Stock publicly traded?
Yes, Oruka Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Oruka Therapeutics, Inc. - Common Stock trade on?
Oruka Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Oruka Therapeutics, Inc. - Common Stock?
The ticker symbol for Oruka Therapeutics, Inc. - Common Stock is ORKA on the Nasdaq Stock Market
What is the current price of Oruka Therapeutics, Inc. - Common Stock?
The current price of Oruka Therapeutics, Inc. - Common Stock is 71.93
When was Oruka Therapeutics, Inc. - Common Stock last traded?
The last trade of Oruka Therapeutics, Inc. - Common Stock was at 10/16/26 04:00 PM ET
What is the market capitalization of Oruka Therapeutics, Inc. - Common Stock?
The market capitalization of Oruka Therapeutics, Inc. - Common Stock is 1.04B
How many shares of Oruka Therapeutics, Inc. - Common Stock are outstanding?
Oruka Therapeutics, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap